Mrna cap analogs with modified phosphate linkage

Abstract

The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.

1 . A compound of formula (I): 
       
         
           
           
               
               
           
         
         or a stereoisomer, tautomer or salt thereof, wherein
 ring B 1  is a modified Guanine; 
 ring B 2  is a nucleobase or a modified nucleobase; 
 X 2  is O, S(O) p , NR 24  or CR 25 R 26  in which p is 0, 1, or 2; 
 Y 2  is —(CR 40 R 41 ) u -Q 0 -(CR 42 R 43 ) v —, in which Q 0  is a bond, O, S(O) r , NR 44 , or CR 45 R 46 , r is 0, 1, or 2, and each of u and v independently is 1, 2, 3 or 4; 
 R 2  is halo, LNA, or OR 3 ; 
 R 3  is H, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, or C 2 -C 6  alkynyl and R 3 , when being C 1 -C 6  alkyl, C 2 -C 6  alkenyl, or C 2 -C 6  alkynyl, is optionally substituted with one or more of halo, OH and C 1 -C 6  alkoxyl that is optionally substituted with one or more OH or OC(O)—C 1 -C 6  alkyl; 
 each of R 20 , R 21 , R 22 , and R 23  independently is-Q 3 -T 3 , in which Q 3  is a bond or C 1 -C 3  alkyl linker optionally substituted with one or more of halo, cyano, OH and C 1 -C 6  alkoxy, and T 3  is H, halo, OH, NH 2 , cyano, NO 2 , N 3 , R S3 , or OR S3 , in which R S3  is C 1 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl, C 3 -C 5  cycloalkyl, C 6 -C 10  aryl, NHC(O)—C 1 -C 6  alkyl, mono-C 1 -C 6  alkylamino, di-C 1 -C 6  alkylamino, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and R S3  is optionally substituted with one or more substituents selected from the group consisting of halo, OH, oxo, C 1 -C 6  alkyl, COOH, C(O)O—C 1 -C 6  alkyl, cyano, C 1 -C 6  alkoxyl, amino, mono-C 1 -C 6  alkylamino, di-C 1 -C 6  alkylamino, C 3 -C 8  cycloalkyl, C 6 -C 10  aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; 
 each of R 24 , R 25 , and R 26  independently is H or C 1 -C 6  alkyl; 
 each of R 27  and R 28  independently is H or OR 29 ; or R 27  and R 28  together form O—R 30 —O; 
 each R 29  independently is H, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, or C 2 -C 6  alkynyl and R 29 , when being C 1 -C 6  alkyl, C 2 -C 6  alkenyl, or C 2 -C 6  alkynyl, is optionally substituted with one or more of halo, OH and C 1 -C 6  alkoxyl that is optionally substituted with one or more OH or OC(O)—C 1 -C 6  alkyl; 
 R 30  is C 1 -C 6  alkylene optionally substituted with one or more of halo, OH and C 1 -C 6  alkoxyl; 
 each of R 40 , R 41 , R 42 , and R 43  independently is H, halo, OH, cyano, N 3 , OP(O)R 47 R 48 , or C 1 -C 6  alkyl optionally substituted with one or more OP(O)R 47 R 48 , or one R 41  and one R 43 , together with the carbon atoms to which they are attached and Q 0 , form C 4 -C 10  cycloalkyl, 4- to 14-membered heterocycloalkyl, C 6 -C 10  aryl, or 5- to 14-membered heteroaryl, and each of the cycloalkyl, heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl is optionally substituted with one or more of OH, halo, cyano, N 3 , oxo, OP(O)R 47 R 48 , C 1 -C 6  alkyl, C 1 -C 6  haloalkyl, COOH, C(O)O—C 1 -C 6  alkyl, C 1 -C 6  alkoxyl, C 1 -C 6  haloalkoxyl, amino, mono-C 1 -C 6  alkylamino, and di-C 1 -C 6  alkylamino; 
 R 44  is H, C 1 -C 6  alkyl, or an amine protecting group; 
 each of R 45  and R 46  independently is H, OP(O)R 47 R 48 , or C 1 -C 6  alkyl optionally substituted with one or more OP(O)R 47 R 48 , and 
 each of R 47  and R 48 , independently is H, halo, C 1 -C 6  alkyl, OH, SH, SeH, or BH 3 . 
 
       
     
     
         2 . The compound of  claim 1 , wherein ring B 1  is 
       
         
           
           
               
               
           
         
       
       in which
 R 1  is C 1 -C 6  alkyl, C 2 -C 6  alkenyl, or C 2 -C 6  alkynyl, each of which is optionally substituted with one or more substituents selected from the group consisting of C 6 -C 10  aryl, C 6 -C 10  aryloxyl, 5-to 10-membered heteroaryl, and 5- to 10-membered heteroaryloxyl, each being optionally substituted with one or more of halo and cyano; 
 each of R a  and R b  independently is H or C 1 -C 6  alkyl; and 
 R c  is H, NH 2 , or C 1 -C 6  alkyl; or R e  and one of R a  and R b , together with the two nitrogen atoms to which they attach and the carbon atom connecting the two nitrogen atoms form a 5- or 6-membered heterocycle which is optionally substituted with one or more of OH, halo, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, and C 2 -C 6  alkynyl, or 
 a stereoisomer, tautomer or salt thereof. 
 
     
     
         3 . The compound of  claim 1 , wherein ring B 2  is 
       
         
           
           
               
               
           
         
       
       in which
 X 1  is N or N + (R 5 ); 
 R 5  is C 1 -C 6  alkyl, C 2 -C 6  alkenyl, or C 2 -C 6  alkynyl, each of which is optionally substituted with one or more substituents selected from the group consisting of C 6 -C 10  aryl, C 6 -C 10  aryloxyl, 5-to 10-membered heteroaryl, and 5- to 10-membered heteroaryloxyl, each being optionally substituted with one or more of halo and cyano; 
 each of R d  and R e  independently is H or C 1 -C 6  alkyl; and 
 R f , when present, is H, NH 2 , or C 1 -C 6  alkyl; or R f  and one of R d  and R e , together with the two nitrogen atoms to which they attach and the carbon atom connecting the two nitrogen atoms form a 5- or 6-membered heterocycle which is optionally substituted with one or more of OH, halo, C 1 -C 6  alkyl, C 2 -C 6  alkenyl, and C 2 -C 6  alkynyl, or 
 a stereoisomer, tautomer or salt thereof. 
 
     
     
         4 . The compound of  claim 3 , being of formula (Ia): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, tautomer or salt thereof. 
     
     
         5 . The compound of  claim 3 , being of formula (Ib): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, tautomer or salt thereof. 
     
     
         6 . The compound of  claim 4 , being of formula (IIa): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, tautomer or salt thereof. 
     
     
         7 . The compound of  claim 5 , being of formula (IIb): 
       
         
           
           
               
               
           
         
       
       or a stereoisomer, tautomer or salt thereof. 
     
     
         8 .- 9 . (canceled) 
     
     
         10 . The compound of  claim 1 , wherein ring B 1  is 
       
         
           
           
               
               
           
         
       
       in which each of R g  and R h  independently is H or C 1 -C 3  alkyl. 
     
     
         11 .- 16 . (canceled) 
     
     
         17 . The compound of  claim 1 , wherein X 2  is O. 
     
     
         18 . The compound of  claim 1 , wherein X 2  is S(O) p . 
     
     
         19 . The compound of  claim 1 , wherein X 2  is NR 24 , in which R 24  is H or methyl. 
     
     
         20 . The compound of  claim 1 , wherein X 2  is CR 25 R 26 , in which each of R 25  and R 26  is H. 
     
     
         21 .- 25 . (canceled) 
     
     
         26 . The compound of  claim 1 , wherein Y 2  is —CH 2 CH 2 — or —CH 2 CH 2 -Q 0 -CH 2 CH 2 —. 
     
     
         27 . The compound of  claim 1 , wherein Y 2  is —(CR 40 R 41 ) u-1 —CH(R 41 )-Q 0 -CH(R 43 )—(CR 42 R 43 ) v-1 —, in which each of u and v independently is 1 or 2. 
     
     
         28 - 31 . (canceled) 
     
     
         32 . The compound of  claim 1 , selected from any of those in Tables 1 and 2, and stereoisomers, tautomers and salts thereof. 
     
     
         33 . The compound of  claim 1 , selected from any of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       and stereoisomers, tautomers and salts thereof. 
     
     
         34 . The compound of  claim 1 , wherein the compound has a residence time of about 10 seconds or longer when binding with the eukaryotic initiation factor 4E (eIF4E) characterized by surface plasmon resonance (SPR). 
     
     
         35 . An RNA molecule whose 5′ end comprises a compound of  claim 1 . 
     
     
         36 . The RNA molecule of  claim 35 , whose 5′ end comprises a compound of formula (IIIa) or (IIIb): 
       
         
           
           
               
               
           
         
       
       wherein the wavy line indicates the attachment point. 
     
     
         37 . The RNA molecule of  claim 1 , wherein the RNA molecule has a half-life that is at least 1.2 times of that of a corresponding natural RNA molecule in a cellular environment. 
     
     
         38 . A kit for capping an RNA transcript comprising a compound of  claim 1 , and an RNA polymerase. 
     
     
         39 .- 41 . (canceled) 
     
     
         42 . A method for synthesizing an RNA molecule whose 5′ end comprises a compound of  claim 1  in vitro, the method comprising reacting unmodified or modified ATP, unmodified or modified CTP, unmodified or modified UTP, unmodified or modified GTP, the compound or a stereoisomer, tautomer or salt thereof, and a polynucleotide template; in the presence an RNA polymerase; under a condition conducive to transcription by the RNA polymerase of the polynucleotide template into one or more RNA copies; whereby at least some of the RNA copies incorporate the compound or a stereoisomer, tautomer or salt thereof to make the RNA molecule.